A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Summary

The purpose of this study is to evaluate the efficacy and safety of permadomide capsules developed by Qilu Pharmaceutical Co., LTD.

Conditions

• Multiple Myeloma
• Recurrent or Refractory

Interventions

DRUG

Pomalidomide

4 mg pomalidomide capsules administered orally

DRUG

Dexamethasone

40 mg dexamethasone tablets administered orally

Sponsors & Collaborators

• Qilu Pharmaceutical Co., Ltd.

  lead INDUSTRY

Principal Investigators

• Wenming Chen, MD, PhD · Beijing Chao Yang Hospital

• Juan Li, MD, PhD · First Affiliated Hospital, Sun Yat-Sen University

• Hongmei Jing, MD, PhD · Peking University Third Hospital

• Huo Tan, MD, PhD · The First Affiliated Hospital of Guangzhou Medical University

• Shunqing Wang, MD, PhD · Guangzhou First People's Hospital

• Ying Zhao, MD, PhD · First People's Hospital of Foshan

• Xun Lai, MD, PhD · Yunnan Cancer Hospital

• Qing Wang, MD, PhD · Guizhou Provincial People's Hospital

• Jinqiao Zhang, MD, PhD · Hebei Medical University Third Hospital

• Lihong Liu, MD, PhD · Hebei Medical University Fourth Hospital

• Baijun Fang, MD, PhD · Henan Tumor Hospital

• Junjun Li, MD, PhD · The First Affiliated Hospital of Nanhua University

• Binghua Wang, MD, PhD · Weihai Central Hospital

• Wei Yang, MD, PhD · Shengjing Hospital

• Wei Wang, MD, PhD · The Affiliated Hospital of Qingdao University

• Ming Hou, MD, PhD · Shandong University Qilu Hospital

• Aili He, MD, PhD · Second Affiliated Hospital of Xi 'an Jiaotong University

• Yafei Wang, MD, PhD · Tianjin Cancer Hospital

• Jie Jin, MD, PhD · The First Affiliated Hospital of Zhejiang University Medical College (Hematology)

• Xuehong Ran, MD, PhD · Weifang People's Hospital

• Jiao Chen, MD, PhD · Sichuan Provincial People's Hospital

• Liping Su, MD, PhD · Shanxi Province Cancer Hospital

• Yanping Ma, MD, PhD · Second Hospital of Shanxi Medical University

• Yanping Song, MD, PhD · Xi 'an Central Hospital

• Congmeng Lin, MD, PhD · Zhangzhou Hospital, Fujian Province

• Quanyi Lu, MD, PhD · Zhongshan Hospital Xiamen University

• Da Gao, MD, PhD · The Affiliated Hospital of Inner Mongolia Medical University

• Wenhong Lai, MD, PhD · The First Affiliated Hospital of Gannan Medical College

• Jianping Hao, MD, PhD · First Affiliated Hospital of Xinjiang Medical University

• Taiwu Xiao, MD, PhD · Liaocheng People's Hospital

• Zhen Cai, MD, PhD · The First Affiliated Hospital of Zhejiang University Medical College (Transplant Center)

• Xin Zhou, MD, PhD · Wuxi People's Hospital

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-01-04

Primary Completion

2022-06-30

Completion

2023-12-31

Countries

• China

Study Locations